Terminated PHASE4 INTERVENTIONAL 1-arm NCT01700790

Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin

A Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir in Combination With Rifampin in HIV-1-infected Patients With Tuberculosis.

Sponsor: Oswaldo Cruz Foundation

Conditions AIDS Tuberculosis

Interventions Lopinavir/ritonavir and ritonavir

Updated 8 times since 2017 Last updated: May 14, 2019 Started: Feb 29, 2016 Primary completion: Nov 17, 2018 Completion: Dec 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

No Further Funding

This PHASE4 trial investigates AIDS and Tuberculosis and is currently terminated or withdrawn. Oswaldo Cruz Foundation leads this study, which shows 8 recorded versions since 2016 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE4
Jun 2019 — Jan 2021 [monthly]

Terminated PHASE4

Status: Active Not Recruiting → Terminated
Jan 2019 — Jun 2019 [monthly]

Active Not Recruiting PHASE4

Status: Recruiting → Active Not Recruiting

▶ Show 3 earlier versions

Jun 2018 — Jan 2019 [monthly]

Recruiting PHASE4
Dec 2017 — Jun 2018 [monthly]

Recruiting PHASE4
Jan 2017 — Dec 2017 [monthly]

Recruiting PHASE4

First recorded

Feb 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Oswaldo Cruz Foundation
University of Miami

Data source: University of Miami

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rio de Janeiro, Brazil